Symbol="NRIX"
AssetType="Common Stock"
Name="Nurix TherapeuticsÂ Inc"
Description="Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company is headquartered in San Francisco, California."
CIK="1549595"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="1700 OWENS STREET, SUITE 205, SAN FRANCISCO, CA, US"
FiscalYearEnd="November"
LatestQuarter="2023-05-31"
MarketCapitalization="414521000"
EBITDA="-159600992"
PERatio="None"
PEGRatio="None"
BookValue="5.46"
DividendPerShare="0"
DividendYield="0"
EPS="-2.88"
RevenuePerShareTTM="1.144"
ProfitMargin="-2.584"
OperatingMarginTTM="-2.71"
ReturnOnAssetsTTM="-0.277"
ReturnOnEquityTTM="-0.598"
RevenueTTM="60935000"
GrossProfitTTM="-145870000"
DilutedEPSTTM="-2.88"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="1.683"
AnalystTargetPrice="27.25"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="14.31"
PriceToBookRatio="1.701"
EVToRevenue="6.41"
EVToEBITDA="-1.536"
Beta="1.612"
num_52WeekHigh="17.64"
num_52WeekLow="8.34"
num_50DayMovingAverage="9.9"
num_200DayMovingAverage="10.62"
SharesOutstanding="48200100"
DividendDate="None"
ExDividendDate="None"
symbol="NRIX"
open="8.61"
high="8.65"
low="8.52"
price="8.54"
volume="145298.00"
latest_trading_day="2023-08-17"
previous_close="8.60"
change="-0.06"
change_percent="-0.6977%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="28"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="72"
Volume_recent_avg="326670"
Change_recent_avg="-0.02"
Delta_recent_avg="0.63"
Variance_recent_avg="0.32"
Change_ratio_recent_avg="-0.26"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="72"
Aroon_momentum_negative="28"
image_negative_thumbnail_id_1="519"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0086.jpeg"
image_negative_thumbnail_id_2="99"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0077.jpeg"
image_neutral_thumbnail_id_1="596"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0003.jpeg"
image_neutral_thumbnail_id_2="567"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0032.jpeg"
image_positive_thumbnail_id_1="949"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0111.jpeg"
image_positive_thumbnail_id_2="688"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0020.jpeg"
image_professor_thumbnail_id_1="1195"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0029.jpeg"
image_professor_thumbnail_id_2="1196"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0030.jpeg"
